BBC3 and neoplasm: Compared with GSK2830371 treatment alone, the combination therapy of SB203580 and GSK2830371 led to decreased levels of PARP cleavage, p53 and its downstream apoptotic effector PUMA and Bax after 6 hrs of treatment, indicating that p38 activation by GSK2830371 potentiates p53 activation and its tumor suppressive function in NB cells (Supplementary Fig. S3).